11,440
Total Claims
$4.0M
Drug Cost
1,004
Beneficiaries
$3,941
Cost/Patient
Peer Comparison vs. 6,382 Endocrinology providers
0%
Cost per patient vs peers
$3,941 vs $3,933 avg
-20%
Brand preference vs peers
41.2% vs 51.2% avg
Brand vs Generic
59% generic
Brand: 4,450 claims · $3.7M
Generic: 6,363 claims · $189K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 422 | $527K |
| Insulin Glargine,hum.Rec.Anlog | 349 | $349K |
| Insulin Lispro | 204 | $347K |
| Dulaglutide | 157 | $278K |
| Insulin Aspart | 142 | $261K |
| Tirzepatide | 178 | $229K |
| Dapagliflozin Propanediol | 151 | $191K |
| Insulin Aspart | 63 | $111K |
| Sitagliptin Phosphate | 80 | $97K |
| Empagliflozin | 66 | $78K |
| Insulin Detemir | 63 | $72K |
| Insulin Regular, Human | 26 | $64K |
| Insulin Lispro | 20 | $63K |
| Insulin Glargine/Lixisenatide | 52 | $61K |
| Insulin Degludec | 22 | $60K |
Prescribing Profile
Patient Profile
71
Avg Age
67%
Female
1.54
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data